Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats

Basit Öğe Kaydı
dc.authoridYaman, Huseyin/0000-0003-4440-3912
dc.contributor.authorKahraman, Cemil
dc.contributor.authorYaman, Huseyin
dc.date.accessioned2021-12-01T18:48:02Z
dc.date.available2021-12-01T18:48:02Z
dc.date.issued2021
dc.department[Belirlenecek]en_US
dc.description.abstractBackground/aim: Hyperbaric oxygen therapy (HBOT) causes insulin sensitivity, but the reason for this is not known yet. The aim of the present study was to investigate the effect of HBOT on insulin sensitivity via resistin, plasminogen activator inhibitor-I (PAI-I), and adiponectin. Materials and methods: The study was designed using HBOT and control groups, with eight rats in each group. After 20 days of HBOT under 2.5 atmospheres for 90 min, the fasting insulin (FI), resistin, PAI-I, homeostatic model assessment of insulin resistance scores (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), fasting plasma glucose (FPG), triglyceride, and high-density lipoprotein cholesterol (HDL-C) in the plasma were measured. The resistin, PAI-I, and adiponectin mRNA expression levels were also measured in the adipose tissue. Results: Compared to the control group, the FI, FPG, and HOMA-IR scores were significantly lower in the HBOT group, whereas the HDL-C and QUICKI scores were found to be higher. In addition, the resistin, adiponectin, and PAI-I mRNA expression levels were also higher in the HBOT group. Conclusion: The present study demonstrated that the HBOT had regulated the FI, FPG, and HDL-C associated with metabolic syndrome and diabetes mellitus. Moreover, the study showed that HBOT causes insulin sensitivity by raising adiponectin.en_US
dc.description.sponsorshipDuzce University Scientific Research Projects UnitDuzce University [2018.16.03.671]en_US
dc.description.sponsorshipThis work was supported by the Duzce University Scientific Research Projects Unit under Grant 2018.16.03.671.en_US
dc.identifier.doi10.3906/sag-2011-76
dc.identifier.endpage1578en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue3en_US
dc.identifier.pmid33705641en_US
dc.identifier.scopus2-s2.0-85109798618en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1572en_US
dc.identifier.urihttps://doi.org/10.3906/sag-2011-76
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10439
dc.identifier.volume51en_US
dc.identifier.wosWOS:000668257500019en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdiponectinen_US
dc.subjectinsulinen_US
dc.subjectinsulin sensitivityen_US
dc.subjectresistinen_US
dc.subjectplasminogen activator inhibitor-Ien_US
dc.subjectHigh-Density-Lipoproteinen_US
dc.subjectCoronary-Heart-Diseaseen_US
dc.subjectAdipose-Tissueen_US
dc.subjectGlucoseen_US
dc.subjectCholesterolen_US
dc.subjectObesityen_US
dc.subjectRisken_US
dc.subjectMenen_US
dc.titleHyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in ratsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10439.pdf
Boyut:
2.34 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu